Treatment with Infliximab in a Patient with Ankylosing Spondylitis and Crohn’s Disease

Authors

  • Simona Rednic Department of Rheumatology, University of Medicine and Pharmacy, Cluj-Napoca, Romania
  • Claudiu Marinescu Department of Rheumatology, University of Medicine and Pharmacy, Cluj-Napoca, Romania
  • Romeo Chira Department of Endoscopy – 1st Medical Clinic, University of Medicine and Pharmacy, Cluj-Napoca, Romania
  • Liliana Rogojan Department of Pathology, University of Medicine and Pharmacy, Cluj-Napoca, Romania
  • Nicolae Rednic 4th Medical Clinic, University of Medicine and Pharmacy, Cluj-Napoca, Romania

Keywords:

Crohn's disease, ankylosing spondylitis, Infliximab

Abstract

The association of Crohn's disease and ankylosing spondylitis is described in up to 30% of cases. Treatment of both conditions is not an easy task. We present the case of a 53 year old woman, diagnosed with colonic Crohn's disease and ankylosing spondilitis, treated initially with increasing doses of sulphasalazine and moderate dose of corticosteroids, with the persistence of severe gastrointestinal and articular symptoms. She underwent therapy with tumor necrosis factor alpha (TNFalpha) inhibitor Infliximab, with a spectacular improvement of symptoms, signs and quality of life.

Downloads

Published

2006-12-01

How to Cite

1.
Rednic S, Marinescu C, Chira R, Rogojan L, Rednic N. Treatment with Infliximab in a Patient with Ankylosing Spondylitis and Crohn’s Disease. JGLD [Internet]. 2006 Dec. 1 [cited 2025 Jun. 30];15(4):379-82. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/2006.4.8

Issue

Vol. 15 No. 4: December 2006

Section

Case Reports